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Bo Zhong, Xiaohan Cai, Snigdha Chennamaneni, Xin Yi, Lili Liu, John J. Pink, Afshin Dowlati, Yan Xu, Aimin Zhou, and Bin Su This article is available at EngagedScholarship@CSU: https://engagedscholarship.csuohio.edu/scichem_facpub/196 shown to protect against N nitrosobis(2 oxopropyl)amine induced pancreatic tumors in hamster [32] . In some in vitro experiments, nimesulide is able to inhibit the proliferation and to increase the apoptosis rate of various types of cancer cells [18,25,33e38] . However, the nimesulide concentrations used in these studies are ranged from 200 to 500 mM, which greatly exceed the concentra tion necessary to inhibit COX 2 activity. These facts suggest that nimesulide inhibits cancer cell growth and induces cancer cell apoptosis independent of COX 2.
JCC76 is a non COX 2 active nimesulide analog ( Fig. 1) [39e41], and it inhibits SKBR 3 breast cancer cell growth with an IC 50 of 1.38 mM, which is about 100 fold more active than nimesulide (Table 1 ). The N Methylation of JCC76 blocks the ionization of the sulfonamide group, which abolishes the potential COX 2 activity [42e44]. In addition, the aromatic nitro group is converted to an amide moiety on the structure of JCC76, which could diminish the potential hepatotoxicity, since nimesulide shows hepatotoxicity due to the multistep nitroreductive bioactivation that produces the hazardous nitroanion radical and nitroso intermediate [45] . Based on the structure of JCC76, more analogs were designed and synthesized in the current studies. Some new analogs such as CSUOH0901 (NSC751382) inhibited SKBR 3 breast cancer cell growth with IC 50 s around 0.1 mMe0.2 mM, which is about 10 fold more active than JCC76 and almost 1000 fold more active than nimesulide. In addition, CSUOH0901 inhibited the growth of a broad range of cancer cell lines with IC 50 s of 0.2 mM to 0.5 mM. It also inhibited the growth of HT29 colorectal xenograft in nude mice as well. All the studies suggest that the newly developed JCC76 derivatives are promising anti cancer drug candidates.
Results and discussion

Compound design and parallel synthesis of JCC76 derivatives
In previous studies, systematic modification was performed on the structure of nimesulide to improve the anti cancer activity and erase the COX 2 inhibitory activity [41, 46] . SAR result suggests that the dimethyl benzyl and methylsulfonamide moieties are critical for the nimesulide analogs to inhibit cancer cell growth (Fig. 1) . Further, the conversion of the nitro group to a bulky amide moiety generated novel anti cancer agent JCC76 [39e41,46] . In the current study, dimethyl benzyl and methylsulfonamide groups which are important for the anti cancer activity of the derivatives were maintained, and we focused on the modification of the amide moiety of JCC76. Various chemical structures including alkyl amide groups, electron donating or withdrawing group substituted ben zamides, bulky or small group substituted benzamides, and heterocyclic amides were introduced at this moiety.
The synthesis is described in Scheme 1. The starting material 2 amino 5 nitrophenol was refluxed with K 2 CO 3 and 2, 5 dimethyl benzyl chloride to obtain compound a. Sodium hydride and methanesulfonyl chloride were added to compound a in dry dimethylformamide (DMF) at room temperature and the reaction mixture was stirred at room temperature overnight to obtain the N,N bimethanesulfonamido b. Compound b was hydrolyzed with 10% NaOH solution to generate c as a monomethanesulfonamido compound. Compound c was treated with sodium hydride and methyl iodine in DMF at room temperature to obtain compound d. Then the nitro group was reduced to an amine group to obtain compound e. Compound e was treated with different substituted acetyl chloride and K 2 CO 3 to generate the substituted benzamides 1e39, respectively. Structures of all the synthesized compounds were determined by 1 H NMR, MS, and their purity was confirmed by HPLC with two mobile phases.
Biological evaluation of the new analogs with breast cancer cell line SKBR 3
The compounds were tested for the inhibition of SKBR 3 breast cancer cell growth (Table 1 ). Subsequently, a detailed structure activity analysis was performed based on the structure and the anti cancer activity. The new derivatives have same core structure as JCC76, the different activity is correlated with the different amide moieties.
For the substituted benzamide moiety in the structure, para position bulky halogen substituted benzamide such as 9 (bromine) with an IC 50 of 0.22 mM and 29 (iodine) with an IC 50 of 0.13 mM show better potency than JCC76, whereas small halogen chlorine at para position (28) slightly decreases the activity with an IC 50 of 2.15 mM. It is also possible that the activity is related to the elec tronegativity or electron density of the halogens. Iodine has the lowest electronegativity and highest electron density, which may contribute to the potent anti cancer activity. 2, 8, 25, 20, and 27, which have single meta substitution groups, display weaker inhibitory activity with IC 50 s ranging from 1.97 mM to 7.34 mM. It seems that single meta substitution is predominated by steric effect. The activity is decreased no matter the substitution is electron donating or withdrawing group. Dual chlorine substitu tion (4 and 14) slightly increases the activity compared to JCC76, with IC 50 of 0.91 mM and 0.80 mM respectively. 1, 2, 3, 7, 8, 15, 21 and 34, which have electron withdrawing groups as substitution, exhibit IC 50 s among 1.0 mMe3.0 mM. The results suggest that electron withdrawing groups such as nitro, cynao, multi fluoro, and trifluoro methyl substituted benzamide do not increase the activity. 26 shows very weaker activity with an IC 50 of 55.35 mM, which possibly is due to the very strong electron withdrawing effect and the meta position steric effect of the di trifluoro methyl groups. Most of the strong electron donating groups such as methoxyl and multi methoxyl substituted benzamide (10, 11, 16, 18 and 19) increase the activity with IC 50 s among 0.19 mMe0.68 mM.
However, para methyl benzamide (33) and para ethyl benzamide (36) show lesser potency with IC 50 s of 2.48 mM and 2.82 mM respectively, although both methyl and ethyl groups are electron donating substitution. It suggests that para position steric effect reduces the activity, but strong electron donating group at para position overall increase the activity because the electron donating Overall, para position of the benzamide is very critical for the anti cancer activity of the JCC76 analogs. Strong electron donating groups at para position significantly increase the activity. Single meta substituted benzamide greatly decreases the activity, no matter it is electron donating or withdrawing group as substitution. Several very potent analogs (5, 9, 10, 16, 18, 29) , which are about 5e10 fold more active than JCC76, share some structure similarity: para position substituted benzamide, or para and meta both electron donating group substituted benzamide. 10, discovered earlier in the study, was named CSUOH0901 and submitted to the Develop mental Therapeutic Program at the National Cancer Institute for screening against 60 human tumor cell lines. It was also investigated for the anti cancer mechanism and in vivo activity in the study.
CSUOH0901 caused cell population concentrated at sub G1 and G2 phase Compound CSUOH0901 significantly inhibited SKBR 3 breast cancer cell growth. It is important to elucidate the anti cancer mechanisms of the compound. When SKBR 3 cells were treated with 0.5 mM and 5 mM of CSUOH0901, cells were accumulated at G2/ M and subG1 phase after 12 h. As for 0.25 mM treatment, this phenomenon was observed after 24 h ( Table 2 ). The results demonstrate that CSUOH0901 was able to inhibit cell mitosis and induce cell apoptosis at similar dosage to inhibit cell growth. JCC76 has been shown in previous studies to induce cell apoptosis via cytochrome c release [39, 40] . It is not surprising that the more potent JCC76 analog CSUOH0901 exhibits better potency to induce cell apoptosis. However, JCC76 did not show good potency to cause cell cycle arrest in previous studies [39, 40] . CSUOH0901 obviously exhibited the cell G2/M phase arresting activity. Therefore, the anti mitosis potency is significantly increased by the structure modifi cation. 0.1 mM CSUOH0901 clearly induced subG1 cell accumulation after 24 h treatment, but no G2/M cell accumulation was observed, suggesting that the compound at low concentrations was able to induce cell apoptosis without affecting the cell replication. It is difficult to determine if the cell apoptosis and cell growth arrested by the compound are correlated or not, since the specific molecular targets of CSUOH0901 still remain unclear. Further investigation is needed to identify the anti cancer molecular targets of these compounds.
Multi cancer cell lines growth inhibition and animal acute toxicity studies of CSUOH0901 Due to the structure novelty and potency of CSUOH0901, it was submitted to the Developmental Therapeutic Program at the National Cancer Institute (assigned with code NSC751382), and was selected by 
Table 2
Summary of altered cell cycle distribution in response to treatment with CSUOH0901 (NSC751382). SKBR-3 cells were treated for different time period with the indicated concentrations of compound. Cells were processed for FACS using propidium iodide staining as described. Percent distribution of cells in each cell cycle phase was displayed. Table 3) .
The compound was also tested for the acute toxicity to deter mine the maximum tolerated dose in nude mice. After a single dose of 400 mg/kg, 200 mg/kg, or 100 mg/kg, the nude mice were observed for a period of 2 weeks. No body weight lost was found in the three mice tested, indicating that the animals were highly tolerable to CSUOH0901.
In vivo investigation
To determine whether the high activity of our compounds at cell culture would be translated into in vivo active anti cancer agents, CSUOH0901 as a representative one was investigated in the tumor xenograft nude mice model. SKBR 3 cells do not readily form xenografts in nude mice, therefore we used a colon cancer HT29 xenograft model to investigate the in vivo activity of the compound, since it significantly inhibited HT29 cell growth in the in vitro study (Developmental Therapeutics Program at National Cancer Institute) with an IC 50 of 0.42 mM (Table 3) . We confirmed the activity of CSUOH0901 in HT29 cells with an MTT cell proliferation assay, and obtained an IC 50 of 0.46 mM. HT29 xenograft is a well established in vivo tumor model, and has been used to test the activity of many anti cancer drug candidates. Nude mice (three mice per group, two tumors per mouse) bearing HT29 xenografts were given daily (5 times per week) intraperitoneal injections (5 mg/kg) of CSUOH0901 for three weeks after the tumor reached a measurable size.
CSUOH0901 treatment significantly decreased the size of the HT29 tumors compared to the control group ( Fig. 2A) . Weights of the mice were not affected by the treatment (Fig. 2B ), suggesting the low toxicity of the compound. After the treatment, the tumors were removed and weighed. CSUOH0901 significantly decreased the tumor weights as well (Fig. 2C) . The results reveal that CSUOH0901 is active in vivo and could be a promising anti cancer drug candidate.
Pharmacokinetic study
CSUOH0901 exhibited potent in vitro and in vivo anti tumor activity. To support future further pharmacological and toxicolog ical study, a pharmacokinetic study of the compound was also performed. CSUOH0901 was administrated to rats intraperitoneally at a dose of 20 mg/kg. Blood samples (150 mL each) were collected from the saphenous veins and femoral veins into heparized tubes at 0 h (before drug administration) and at 0.25, 0.5, 1, 2, 4, 8 and 24 h after dosing. The peripheral blood drug level was then determined with LC MS/MS. The mean CSUOH0901 concentration in plasma versus time profile was presented in Fig. 3 . Peak drug concentra tions were observed at 2 h after administration and reached nearly1500 ng/mL. The pharmacokinetic parameters were calcu lated by using non compartmental model. The estimated phar macokinetic parameters including the terminal phase elimination half life (T 1/2 ), the area under the plasma concentration time curve (AUC) from time 0 to time of the last measurable concen tration (AUC (0-t) ), the volume of distribution (V z/F), the total body clearance (Cl /F ), and the mean residence time (MRT) from time 0 to time of the last measurable concentration (MRT (0-t) ) are listed in Table 4 . The half life and volume of distribution of the compound is relatively lower compared with more hydrophobic anti cancer drugs such as Taxol [47] , suggesting the compound has better drug like characters than Taxol. The good bioavailability of the compound recommends further drug development of these small molecule anti cancer agents.
Conclusion
The structural modifications of nimesulide have been effective in abolishing its COX 2 inhibiting property and reducing its hepa totoxicity. Among the new derivatives synthesised, compounds 5, 9, 10 (CSUOH0901), 16, 18 and 29 have exhibited good growth inhibitory activity against SK BR 3 breast cancer cells at low nanomolar concentrations. CSUOH0901 displayed good potency to inhibit the growth of a broad range of cancer cell lines and demonstrated minor animal toxicity. The in vivo tumor suppression activity and pharmacokinetic results of CSUOH0901 suggest that the drug candidate has great clinical application potential.
Experimental section
Chemistry
Chemicals were commercially available and used as received without further purification unless otherwise noted. Moisture sensitive reactions were carried out under a dry argon atmosphere in flame dried glassware. Solvents were distilled before use under argon. Thin layer chromatography was performed on precoated silica gel F254 plates (Whatman). Silica gel column chromatog raphy was performed using silica gel 60A (Merck, 230 400 Mesh), and hexane/ethyl acetate was used as the elusion solvent. Mass spectra were obtained on the Micromass QTOF Electrospray mass spectrometer at Cleveland State University MS facility Center. Melting point was recorded with a Mel Temp melting point appa ratus. All the NMR spectra were recorded on a Varian 400 MHz in either DMSO d 6 or CDCl 3 . Chemical shifts (d) for 1 H NMR spectra are reported in parts per million to residual solvent protons. The IR spectra were obtained on a Bruker ALPHA FT IR spectrometer with ATR module. For the HPLC analysis, a 1.00 mg/mL stock solution of each standard was prepared in either methanol or acetonitrile. The HPLC system consists of two LC 20AD pumps, a DGU 20A 3 degasser, a SIL 20AC autosampler, and a CBM 20A module (Shimazu, Tokyo, Japan). The chromatographic separation was performed on a Luna C18 column (2.0 mm Â 150 mm, 5 mm) with a guard column (2 mm Â 40 mm, 5 mm) from Phenomenex (Torrance, CA, USA) at room temperature with a flow rate of 0.2 mL/min. Two mobile phases (10 mM ammonium acetate in 90% methanol or acetonitrile) were employed to run 15 min. An injection volume of 5e15 mL was used. The UV detector was set up at 290 and 256 nM.
Compounds aee were prepared as described by Su et al. [41, 46] .
General procedure for the preparation of the substituted benzamide 1e39 K 2 CO 3 (5 mmol, 5eq) and substituted acyl chloride (1.2 mmol, 1.2 eq) were successively added to a solution of the aniline e (1.0 mmol, 1.0 eq) in 3 mL dry 1, 4 dioxane and the mixture was stirred at room temperature overnight. 10 mL H 2 O and 3 mL saturated aqueous Na 2 CO 3 was added to the mixture and it was stirred at room temperature overnight. The precipitated solid was collected by filtration and purified by silica gel column chromatography. 
Pharmacological studies
Cell culture SKBR 3, HT29 cells were obtained from ATCC (Rockville, MD). All cells were maintained in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mmol/L L Glutamine, 1 mmol/L sodium pyruvate, 100 U/mL penicillin streptomycin. FBS was heat inactivated for 30 min in a 56 C water bath before use. Cell cultures were grown at 37 C, in a humidified atmosphere of 5% CO 2 in a Hereaus CO 2 incubator.
Cell viability analysis
The effect of nimesulides derivatives on SKBR 3 and HT29 cell viability was assessed by using the 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyl 2H tetrazolium bromide assay in six replicates. Cells were grown in RPMI1640 medium in 96 well, flat bottomed plates for 24 h, and were exposed to various concentrations of JCC76 derivatives dissolved in DMSO (final concentration 0.1%) in media for 48 h. Controls received DMSO vehicle at a concentration equal to that in drug treated cells. The medium was removed, replaced by 200 ml of 0.5 mg/mL of 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyl 2H tetrazolium bromide in fresh media, and cells were incubated in the CO2 incubator at 37 C for 2 h. Supernatants were removed from the wells, and the reduced 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyl 2H tetrazolium bromide dye was solubilized in 200 ml/ well DMSO. Absorbance at 570 nm was determined on a plate reader. 
Flow cytometry analysis
Preparation of calibration standards and quality controls (QC) samples
The stock standard solutions of CSUOH0901 were prepared by dissolving in DMSO it at 1 mg/mL and stored at 20 C. One set of CSUOH0901 working solutions at 3,10, 20,100, 200 and 1000 ng/mL, prepared by serial diluting stock solution with 50% acetonitrile in water, was used for calibration standards. Another set of JCC76 working solutions at 3, 9, 90, and 900 ng/mL was made in the similar way and used for QC samples. All of the working solutions were freshly prepared before use. Calibration standards were prepared by spiking 5 mL different CSUOH0901 working solutions into 50 mL blank rat plasma to give the final concentration of CSUOH0901 at 0.3, 1, 2,10, 2 and 100 ng/mL. The QC samples were prepared in same way as the calibration standards at four different levels of 0.3, 0.9, 9 and 90 ng/mL, representing lower limit of quantitation (LLOQ), low QC (LQC), middle QC (MQC) and high QC (HQC) of CSUOH0901 in plasma. All of the calibration standards and QC samples were further treated in the same preparation procedure.
Pharmacokinetic study
Male SpragueeDawley rats (each weight 300e350 g) were purchased from Charles River Laboratories International (Spencer ville, OH, USA). Animals were housed in a 12 h light/dark cycle room with free access to food and water for at least 7 days to adapt the environment. All the animal experiment procedures were per formed under the guideline approved by Institutional Animal Care and Use Committee at Cleveland State University.
Before the intraperitoneal administration of CSUOH0901 at a single dose of 20 mg/kg (PBS with 01% Tween80, 20% DMSO as vehicle), animals were fasted overnight but with free access of water. Blood samples of 150 mL each were collected from the saphenous veins and femoral veins into heparized tubes at 0 h (before drug administration) and at 0.25, 0.5, 1, 2, 4, 8 and 24 h after dosing. The blood samples were centrifuged immediately at 10,000 rpm for 5 min in room temperature. The plasma samples were separated and store at e20 C until analysis.
Plasma concentrations of CSUOH0901 were determined by an LCeMS/MS method developed and validated for this study. The LC MS/MS method consisted of a Shimazu HPLC system ((Shimazu, Tokyo, Japan) and an AB Sciex QTrap 5500 mass spectrometer equipped with an electrospray ionization source (ABI Sciex, Tor onto, Canada). The chromatographic separation was achieved using a C 18 column (2.0 mm Â 150 mm, 5 mm) together with 0.5 mM ammonium formate in 90% methanol for isocratic elution. The eluates were detected using multiple reaction monitoring (MRM) mode for CSUOH0901 (m/z 483.3 to 404.3) and the internal stan dard JCC76 (m/z 445 to 366.3). The liquideliquid extraction method using the mixture of tert butyl methyl ether and n hexane (1:1, v/v) was optimized for plasma sample pretreatment. This analytical method was validated over the concentration range of 0.1e100 ng/ mL (r2 ! 0.999). The intra and inter assay variability (% coefficient of variation) and mean bias (% relative error) were evaluated and less than 15%. Plasma quantified above the highest concentration of the standard curve were diluted with blank plasma and reanalyzed.
The concentration of CSUOH0901 in rat plasma versus time profiles were analyzed to estimate pharmacokinetics parameters using WinNonlin -t) ), the volume of distribution (V z/F), the total body clearance (Cl /F ), and the mean residence time (MRT) from time 0 to time of the last measurable concentration (MRT (0-t) ) were determined.
